Global Cholesterol-Lowering Drugs Market Set To Grow To $23bn By 2021

13 August 2018
Pharma

Visiongain’ has launched a new pharma report Global Cholesterol-Lowering Drugs Market 2017-2027: Statins and Fixed-Dose Combinations, Cholesterol Absorption Inhibitors, Ion Exchange Resins, Fibrates, PCSK9 Inhibitors, Novel Drugs

Shifting diets and lifestyle choices are associated with increases in wealth and the level of development of a country’s economy. With the rapid growth seen in markets such as the BRIC markets, as well as other nations such as Mexico, rates of high cholesterol have been increasing in these nations. Many of the drugs currently used for the control of cholesterol levels have or are soon going to see their patents expire, allowing for generic competition. This has been particularly prevalent among statins, as many of these were developed some time ago.

There is a strong pipeline for cholesterol-lowering drugs; many of which will launch within the next two to three years. New drug classes such as PCSK9 inhibitors will open up new areas of treatment, as they allow further treatment of patients with very high cholesterol levels. The impact of new treatments will lead to a significant rise in global revenues in the market. The addition of further indications for these new products at a later date would allow for further expansion of their use.

The lead analyst of the report commented “Visiongain believes the major drivers of growth in the global cholesterol-lowering drugs market will be: increasing demand for cholesterol-lowering drugs due to population growth and the increasing prevalence of high cholesterol, improvements in the management and treatment of high cholesterol, increasing healthcare expenditure, especially in a number of emerging economies and he launch of new drugs such as PCSK9 inhibitors”

Leading companies featured in the report include AstraZeneca, Merck & Co, Pfizer, Kowa Company, Daiichi Sankyo, AbbVie, Novartis, Sanofi, Amgen, Bristol-Myers Squibb (BMS).

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongainglobal.com or call her on +44 (0) 207 336 6100

About visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-to-business reports cusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes Ophthalmic Devices Market Report 2022-2032

The number of people who are blind or have poor vision is expected to rise considerably in the coming years. The growing elderly population is one of the key drivers of the Ophthalmic Devices Market’s upward trend.

19 April 2022

Read

Visiongain Publishes Vaccine Contract Manufacturing Market Report 2022-2032

The growing global health system has made significant contributions to protecting and promoting human health. However, long-standing, developing, and reemerging infectious disease risks continue to plague the planet

13 April 2022

Read

Visiongain Publishes Pharmaceutical Contract Manufacturing Market Report 2022-2032

The major driving factor contributing towards the growth of pharmaceutical contract manufacturing market are increase in investments in pharmaceutical R&D, rise in number of patent expiry, rising demand of generic drugs, and investment in advanced manufacturing technologies. However, use of serialization can thwart the market growth.

13 April 2022

Read

Visiongain Publishes Vaccine Sales Market Report 2022-2032

Rising epidemic potential, a growing emphasis on therapeutic vaccines, and new markets are projected to provide considerable growth prospects for vaccine providers.

30 March 2022

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever